Practical Guidance is committed to amplifying diverse voices of attorneys across all differences, including gender and race. If you are interested in writing for Practical Guidance, please let us know...
Earlier this year, the U.S. Environmental Protection Agency (EPA) and U.S. Army Corps of Engineers published a final rule 1 to revise the definition of waters of the United States. THIS ARTICLE DISCUSSES...
By: Cameron Kinvig , PRACTICAL GUIDANCE ENERGY & UTILITIES ATTORNEY EDITOR This article provides you and your clients with an overview of the federal environmental regulation affecting the oil and...
Sustainability-Linked Loans Overview Sustainability-linked loans are loans where the economic characteristics can vary depending on whether the borrower achieves ambitious, material, and quantifiable...
By: M. Shams Billah , BARNES & THORNBURG LLP, NEW YORK This article discusses guidance for borrowers and private equity sponsors entering into private credit loans with nonbank lenders in the middle...
Copyright © 2023 LexisNexis and/or its Licensors.
By: Matthew D. Jenkins, Hunton Andrews Kurth LLP
This article provides an overview of compliance obligations and federal False Claims Act (FCA) risks to healthcare and life sciences companies arising out of three funding streams made available in response to the COVID-19 pandemic: (1) Medicare’s Advance Payment Program, (2) the Provider Relief Fund, and (3) the Paycheck Protection Program.
When you advise a healthcare company that receives federal funds about its compliance obligations, a basic understanding of the FCA is essential.
The FCA imposes civil penalties on persons who knowingly or with reckless disregard: CLICK HERE TO READ THE FULL ARTICLE IF YOU ARE A PRACTICAL GUIDANCE SUBSCRIBER